Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Cardiologists and surgeons perform world’s first robot-assisted TEER
A 62-year-old women presented with severe MR and recurrent heart failure episodes. Initial data suggest the procedure was a success.
Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF
Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.
Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke
All participants were free of ASCVD and had no history of statin use at the start of the study.
Diabetic cardiomyopathy treatment shows promise in ARISE-HF
James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."
Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients
The popular high-fat, low-carb diet is associated with multiple short-term benefits, but they appear to diminish over time.

durbin-ama-opioid. The American College of Cardiology (ACC) and American Heart Association (AHA) have published new guidelines focused on the diagnosis, treatment and management of patients with chronic coronary disease (CCD).

Canagliflozin linked to fewer deaths, heart failure hospitalizations for type 2 diabetics

Canagliflozin reduced the risk of death or hospitalization for heart failure by 22 percent among patients with type 2 diabetes and a high risk of cardiovascular disease, according to results of the CANVAS trial presented March 11 at the American College of Cardiology’s scientific session and published simultaneously in Circulation.

March 19, 2018

Mortality risk model combines EHR data, language processing to account for frailty

Applying natural language learning and deep neural networks to mortality risk models could help predict cardiovascular outcomes with more accuracy than modern support vector machines, researchers said at the 67th annual American College of Cardiology conference in Orlando.

March 16, 2018

Heart Failure

Cardiologists and surgeons perform world’s first robot-assisted TEER

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients